TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06418555

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A home rehabilitation program centered on exercise
Description: Establish a multidisciplinary team, with team members combining clinical experience, summarizing the best evidence as the basis, and using the theory of behavior change wheels as the framework, to preliminarily construct a home-based cardiac rehabilitation plan suitable for TAVR patients in China's national conditions. Conduct expert consultation using the Delphi method to form the final version of the home cardiac rehabilitation plan for TAVR patients.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A home rehabilitation program centered on exercise
Description: Establish a multidisciplinary team, with team members combining clinical experience, summarizing the best evidence as the basis, and using the theory of behavior change wheels as the framework, to preliminarily construct a home-based cardiac rehabilitation plan suitable for TAVR patients in China's national conditions. Conduct expert consultation using the Delphi method to form the final version of the home cardiac rehabilitation plan for TAVR patients.
Study: NCT05305287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: An insulin sensitizer and anti-diabetic agent. Participants will be started on 15 mg/day, increased to 30 mg/day at week 2 and then to 45 mg/day at week 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: An insulin sensitizer and anti-diabetic agent. Participants will be started on 15 mg/day, increased to 30 mg/day at week 2 and then to 45 mg/day at week 4.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for pioglitazone

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for pioglitazone
Study: NCT05854225

Intervention type: DRUG
Group type: OTHER
Intervention: Thiotepa
Description: Thiotepa is an alkylating agent that is routinely used in solid tumors, but it is able to cross the blood-brain barrier into the center.
Study: NCT06580418

Intervention type: OTHER
Intervention: Additional biopsies and blood samples
Description: During the endoscopic procedure planned for IBD patients following standard clinical practice, the endoscopist will decide the number and location of additional biopsy samples (up to 8) collected for the study. Participation in this study also requires the removal of three additional blood samples.

Intervention type: OTHER
Intervention: Additional biopsies and blood samples
Description: During the endoscopic procedure planned for IBD patients following standard clinical practice, the endoscopist will decide the number and location of additional biopsy samples (up to 8) collected for the study. Participation in this study also requires the removal of three additional blood samples.
Study: NCT06462911

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOme-Based Self-management and COgnitive Training CHanges lives (HOBSCOTCH) - Spanish/Espanol
Description: HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life. The entire HOBSCOTCH program has been translated into Spanish for people with epilepsy who speak Spanish.
Study: NCT06580405

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KNP-1000 Apheresis System
Description: sFlt-1 is removed from the participants' plasma through treatment.
Study: NCT06579924

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Disposable mini-PCNL
Description: Mini-PCNL carried out using disposable scope

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Re-usable mini-PCNL
Description: Mini-PCNL carried out using re-usable scope
Study: NCT06374446

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classical Treatment
Description: This group in our study exercises 2 days a week, 2 repetitions a day, 3 sets of 15 repetitions for 6 weeks. Upper and lower extremity exercises are available, including shoulder flexion and abduction, hip and knee exercises. Active breathing cycle is used as breathing exercises. Active respiratory cycle; Includes breathing control, thoracic expansion exercises and huffing. These are done for 6 weeks, along with upper and lower extremity exercises. All evaluations are made at the beginning and end of the groups.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Combined with Classical Treatment
Description: This group in our study exercises 2 days a week, 2 repetitions a day, 3 sets of 15 repetitions for 6 weeks. Upper and lower extremity exercises are available, including shoulder flexion and abduction, hip and knee exercises. Active breathing cycle is used as breathing exercises. Active respiratory cycle; Includes breathing control, thoracic expansion exercises and huffing. These are done for 6 weeks, along with upper and lower extremity exercises. In addition, individuals can take a 30-minute walk in the forest, do yoga, etc. with virtual reality glasses. Videos for relaxation will be shown. All evaluations will be made at the beginning and end of the groups.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Individuals in this group are given 30-minute walks in the forest, yoga, etc. with virtual reality glasses, 2 days a week, 2 times a day for 6 weeks. Videos for relaxation will be shown. All evaluations will be made at the beginning and end of the groups.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: This group will be given a handbook explaining the importance of exercise in individuals with long-term symptoms after Covid.
Study: NCT05757492

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHS-006 (anti-TIGIT)
Description: Arm A participants will receive CHS-006 administered via IV Q3W.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHS-006 (anti-TIGIT)
Description: Arm A participants will receive CHS-006 administered via IV Q3W.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHS-006 (anti-TIGIT)
Description: Arm A participants will receive CHS-006 administered via IV Q3W.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHS-006 (anti-TIGIT)
Description: Arm A participants will receive CHS-006 administered via IV Q3W.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: toripalimab (anti-PD-1)
Description: Arm B participants will receive toripalimab administered via IV Q3W.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: toripalimab (anti-PD-1)
Description: Arm B participants will receive toripalimab administered via IV Q3W.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: toripalimab (anti-PD-1)
Description: Arm B participants will receive toripalimab administered via IV Q3W.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: toripalimab (anti-PD-1)
Description: Arm B participants will receive toripalimab administered via IV Q3W.
Study: NCT06072534

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mivacurium Chloride
Description: emergence modified sequence intubation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mivacurium Chloride
Description: emergence modified sequence intubation
Study: NCT05860127

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Referral for Cognitive Stimulation Therapy
Description: Physician will review participant eligibility for CST treatment and offer referral based on clinical judgement

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No change to Standard of Care
Description: Participants will not receive referral from a physician. They will continue with standard of care at their site.
Study: NCT04905615

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Data-driven and teacher led school based strategies.
Description: The intervention is individualised to each school, depending on the teacher led strategies which are data-informed
Study: NCT06140108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: Each participant will receive empagliflozin 10mg daily for 3 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MetFORMIN 500 Mg Oral Tablet
Description: Each participant will receive metformin 1000mg daily for 3 months.
Study: NCT04721925

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social media messaging
Description: A motivational interviewing-based intervention delivered via private health coaching on social media for 8 weeks.
Study: NCT04610931

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality-Enhanced Cognitive Behavioral Therapy (VR-CBT)
Description: Participants are smokers seeking treatment. Patients will be randomized into one of the 2 intervention groups.~In all cases, patients will receive nicotine replacement therapy. The second physician in charge of the usual tobacco monitoring will adjust the dosage.~Subjects in the usual treatment group will receive 6 weekly individual cognitive behavior therapy sessions lead by a psychologist. The content of CBT is similar in both groups. Subjects in the Virtual Reality group will receive 6 weekly individual CBT sessions followed by 6 virtual therapy sessions. Virtual therapy consists of exposing the patient to 3D situations considered to cause a high risk of smoking relapse and aiming to reduce signal reactivity by extinction. At each session, a neutral exposure will be given at the beginning to facilitate immersion and emergence of the session with a duration determined according to the sensitivity of each patient. Exposure is stopped when the craving approaches the baseline level.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive behavior therapy
Description: Participants are smokers seeking treatment. Patients will be randomized into one of the 2 intervention groups. In all cases, patients will receive nicotine replacement therapy. The second physician in charge of the usual tobacco monitoring will adjust the dosage.~Subjects in the usual treatment group will receive 6 weekly individual cognitive behavior therapy sessions lead by a psychologist. The content of CBT is similar in both groups.
Study: NCT06525948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTPO
Description: rhTPO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporin A
Description: cyclosporine A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporin A
Description: cyclosporine A
Study: NCT06178146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymosin Alpha1
Description: Based on the conventional treatment, subcutaneous injection of Tα-1 (1.6 mg, qd) in Week 1; and in Week 2, subcutaneous injection of thymalfasin 1.6 mg, 3 times a week, followed by twice a week for 1 month since Week 3.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immunosuppressant
Description: Grade 2 irAEs: corticosteroid alone Grade 3 and above irAEs: corticosteroids combined with other immunosuppressants Steroid-refractory irAE: After 48-72 hours of systemic steroid therapy, the symptoms do not improve or worsen, and the second-line immunosuppressant therapy is adopted.
Study: NCT05727410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab, docetaxel, cisplatin Group
Description: Patients will be treated with nivolumab 360mg and plus docetaxel 60mg/m2 and cisplatin 60mg/m2 every 3 weeks for 3 cycles and will be evaluated for the operability. Patients with R0 resection will receive radiation 59.4 Gy in 27 fractions. Boost RT of 6.6 Gy in 3 fractions to tumor bed and/or gross tumor will be optional in patients who had R1-R2 resection. If tumors are regarded inoperable after neoadjuvant therapy (due to high risk of post-operative complication, or metastatic disease), they will be off from this study and receive the appropriate treatment, though they will be also included in the efficacy and safety analyses.
Study: NCT05449964

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SCALING AND ROOT PLANING (SRP)in single sitting
Description: SCALING AND ROOT PLANING (SRP) IS THE PRIMARY COURSE OF NON-SURGICAL PERIODONTAL TREATMENT THAT INVOLVES REMOVAL OF SUPRA-GINGIVAL AND SUB-GINGIVAL BIOFILM AND CALCULUS FOLLOWED BY THOROUGH ROOT PLANING.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SCALING AND ROOT PLANING (SRP)in two sittings
Description: SCALING AND ROOT PLANING (SRP) IS THE PRIMARY COURSE OF NON-SURGICAL PERIODONTAL TREATMENT THAT INVOLVES REMOVAL OF SUPRA-GINGIVAL AND SUB-GINGIVAL BIOFILM AND CALCULUS FOLLOWED BY THOROUGH ROOT PLANING.
Study: NCT06509256

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid injection
Description: work aims to evaluate the role of tranexamic acid in bleeding control in gynecomastia surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid injection
Description: work aims to evaluate the role of tranexamic acid in bleeding control in gynecomastia surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid injection
Description: work aims to evaluate the role of tranexamic acid in bleeding control in gynecomastia surgery
Study: NCT06291610

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Clinical trial decision support intervention
Description: 1. a patient decision aid tailored to clinical trial participation~2. decision coaching consultations carried out by trained healthcare professionals.~3. a training program in decision coaching will be an integrated part of the intervention.
Study: NCT05569746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INM004
Description: Two 4 mg/kg doses of INM004, 24 h (±2 h) apart, will be assessed. Each dose will be administered as an intravenous infusion during 50 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SoC
Description: Standard of care
Study: NCT06580847

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Singing
Description: 12 week choir program consisting of 1.5 hours of in-person instruction per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audiobook Club
Description: 12 week audiobook club program consisting of 1.5 hours of in-person discussion per week.
Study: NCT06178146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunosuppressant
Description: Grade 2 irAEs: corticosteroid alone Grade 3 and above irAEs: corticosteroids combined with other immunosuppressants Steroid-refractory irAE: After 48-72 hours of systemic steroid therapy, the symptoms do not improve or worsen, and the second-line immunosuppressant therapy is adopted.
Study: NCT04712006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64304500
Description: Participants will be administered with JNJ-64304500 SC (Dose 1 or 2) injection on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64304500
Description: Participants will be administered with JNJ-64304500 SC (Dose 1 or 2) injection on Day 1.
Study: NCT05379543

Intervention type: OTHER
Intervention: Echocardiography
Description: Echocardiography is performed using a GE Vingmed Ultrasound System (GE Healthcare, Horten, Norway), by an experienced expert. Morphological and functional parameters of the heart are measured in a consistent manner.

Intervention type: OTHER
Intervention: Echocardiography
Description: Echocardiography is performed using a GE Vingmed Ultrasound System (GE Healthcare, Horten, Norway), by an experienced expert. Morphological and functional parameters of the heart are measured in a consistent manner.

Intervention type: OTHER
Intervention: Echocardiography
Description: Echocardiography is performed using a GE Vingmed Ultrasound System (GE Healthcare, Horten, Norway), by an experienced expert. Morphological and functional parameters of the heart are measured in a consistent manner.

Intervention type: OTHER
Intervention: Echocardiography
Description: Echocardiography is performed using a GE Vingmed Ultrasound System (GE Healthcare, Horten, Norway), by an experienced expert. Morphological and functional parameters of the heart are measured in a consistent manner.
Study: NCT04547374

Intervention type: OTHER
Intervention: GaH Intervention
Description: Patients in this cohort will be referred for management/intervention with GaH.~However, the purpose of this program is not to define, control, or evaluate the specific details of the GaH process or procedure, but to evaluate its effectiveness as an alternative clinical care path in this setting. As such, the specific details and actions of the GaH care team in each patient interaction are left to their medical discretion.
Study: NCT06029101

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: posterior fossa craniectomy with or without duraplasty
Description: craniectomy of occipital bone and duroplasty with graft to expand the shallow posterior fossa and reposition the cerebellar tonsils.
Study: NCT06240585

Intervention type: OTHER
Intervention: presence of gastroparesis as an early sign for sepsis (bacteremia)- measurement of gastric residual volume
Description: presence of gastroparesis as an early sign for sepsis (bacteremia)-measurement of gastric residual volume
Study: NCT05263466

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET-MRI
Description: For the diagnostic imaging aspect included in this pilot study, \[68Ga\]PSMA-11 will be used. This is a peptidomimetic agent with a covalently bound chelator (HBED-CC) that is FDA-approved in prostate cancer imaging. We will use PET-MRI to visualise a) the concentration and b) the distribution of this tracer to establish a functional map of primary brain tumour activity

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain tumour biopsy
Description: All patients included in our study will undergo stereotactic surgery for biopsy/resection of the tumour as part of the standard of care at KCH. During this study we will not vary from the surgical standard of care for primary brain tumours and will only extend the surgery time due to additional stereotactic biopsies (an additional 3 biopsies increasing the time of the operation by \~30 minutes). Professor Ashkan (KCH) has defined the additional surgical risk of performing these biopsies to be \~0%, since targeted biopsies will only be taken within the tumour just before resection. The stereotactic biopsy may be targeted to areas of high \[68Ga\]PSMA SUV within the tumour as defined by the PET MRI scan.
Study: NCT05203484

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multielecotrde Mapping
Description: Multielectrode Mapping with Pentaray/Octaray

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Point-by-point mapping
Description: Point-by-point mapping with QDot
Study: NCT05204589

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aerosolized Ad5-nCoV
Description: Aerosolized Ad5-nCoV is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.1 ml / dose, contains 1×10\^10 virus particles of recombinant replication defective human type 5 adenovirus expressing SARS-CoV-2 S protein, aerosol inhalation.
Study: NCT06577545

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioural Lifestyle (BL)
Description: 24-week behavioural lifestyle intervention
Study: NCT05204589

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aerosolized Ad5-nCoV
Description: Aerosolized Ad5-nCoV is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.1 ml / dose, contains 1×10\^10 virus particles of recombinant replication defective human type 5 adenovirus expressing SARS-CoV-2 S protein, aerosol inhalation.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated SARS-CoV-2 vaccine
Description: Inactivated SARS-CoV-2 vaccine is homologous to the priming series which have been administered to the subjects, produced by SinoVac Biotech Co,. Ltd, Beijing Institute of Biological Products Co,. Ltd, Wuhan Institute of Biological Products Co,. Ltd, or Biokangtai.
Study: NCT05038280

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Let's Talk about Children intervention
Description: The LTC -intervention includes two steps: Let´s Talk about Children discussion and Let´s Talk about Children network meeting. Students, students´ parents, and a teacher take part in the LTC -discussion. The LTC logbook is used as the framework for the discussions. The LTC discussion depicts the child's ordinary day in all developmental contexts and an action plan is made with parents to enhance the identified strengths and to give support in vulnerabilities. When the action plan is difficult to carry out without further participants, the LTC-Network meeting is planned with parents (and sometimes also the child). LTC-Network meeting provides a forum for case-based cross-sectoral collaboration, including also the families and their social network.
Study: NCT04792697

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Increase morning bright light
Description: Participants will wear Re-Timer bright glasses for 30 minutes each morning upon rising

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decrease evening blue light
Description: Participants will wear blue light blocker goggles for 2 hours before bed

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Scheduling
Description: Participants will advance their bedtime by 1.5 hours and regularize their wake time

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monitor sleep, mood, and substance use
Description: Participants will complete smartphone-based sleep, mood, and substance use monitoring

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Monitor sleep, mood, and substance use
Description: Participants will complete smartphone-based sleep, mood, and substance use monitoring
Study: NCT04732091

Intervention type: PROCEDURE
Intervention: Therapeutic ultrasound with 20 usec
Description: A custom designed high mechanical index (MI) impulses at 4-20 usec and \>1.0 mechanical index designed for the 1.8 MHz S5-1 transducer

Intervention type: PROCEDURE
Intervention: Therapeutic ultrasound with 20 usec
Description: A custom designed high mechanical index (MI) impulses at 4-20 usec and \>1.0 mechanical index designed for the 1.8 MHz S5-1 transducer

Intervention type: PROCEDURE
Intervention: Therapeutic ultrasound with 20 usec
Description: A custom designed high mechanical index (MI) impulses at 4-20 usec and \>1.0 mechanical index designed for the 1.8 MHz S5-1 transducer

Intervention type: PROCEDURE
Intervention: Therapeutic ultrasound with 20 usec
Description: A custom designed high mechanical index (MI) impulses at 4-20 usec and \>1.0 mechanical index designed for the 1.8 MHz S5-1 transducer

Intervention type: PROCEDURE
Intervention: Therapeutic ultrasound with 20 usec
Description: A custom designed high mechanical index (MI) impulses at 4-20 usec and \>1.0 mechanical index designed for the 1.8 MHz S5-1 transducer